par Schuler, M;Awada, Ahmad 
;Harter, Philipp;Canon, Jean-Luc;Possinger, Kurt;Schmidt, M;De Greve, Jacques;Neven, Patrick;Dirix, Luc Y;Jonat, Walter;Beckmann, Matthias W;Schütte, Jochen;Fasching, Peter A;Gottschalk, Nina;Besse-Hammer, Tatiana;Fleischer, Frank;Wind, Sven;Uttenreuther-Fischer, Martina;Piccart-Gebhart, Martine ;Harbeck, Nadia
Référence Breast cancer research and treatment, 134, 3, page (1149-1159)
Publication Publié, 2012-08
;Harter, Philipp;Canon, Jean-Luc;Possinger, Kurt;Schmidt, M;De Greve, Jacques;Neven, Patrick;Dirix, Luc Y;Jonat, Walter;Beckmann, Matthias W;Schütte, Jochen;Fasching, Peter A;Gottschalk, Nina;Besse-Hammer, Tatiana;Fleischer, Frank;Wind, Sven;Uttenreuther-Fischer, Martina;Piccart-Gebhart, Martine ;Harbeck, NadiaRéférence Breast cancer research and treatment, 134, 3, page (1149-1159)
Publication Publié, 2012-08
Article révisé par les pairs
| Titre: |
|
| Auteur: | Schuler, M; Awada, Ahmad; Harter, Philipp; Canon, Jean-Luc; Possinger, Kurt; Schmidt, M; De Greve, Jacques; Neven, Patrick; Dirix, Luc Y; Jonat, Walter; Beckmann, Matthias W; Schütte, Jochen; Fasching, Peter A; Gottschalk, Nina; Besse-Hammer, Tatiana; Fleischer, Frank; Wind, Sven; Uttenreuther-Fischer, Martina; Piccart-Gebhart, Martine; Harbeck, Nadia |
| Informations sur la publication: | Breast cancer research and treatment, 134, 3, page (1149-1159) |
| Statut de publication: | Publié, 2012-08 |
| Sujet CREF: | Cancérologie |
| Mots-clés: | Afatinib |
| EGFR TKI | |
| HER2-negative breast cancer | |
| Metastatic breast cancer | |
| Triple-negative breast cancer | |
| MeSH keywords: | Adult |
| Aged | |
| Aged, 80 and over | |
| Antineoplastic Agents -- adverse effects -- pharmacology -- therapeutic use | |
| Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology | |
| Cohort Studies | |
| Female | |
| Humans | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Protein Kinase Inhibitors -- adverse effects -- pharmacology -- therapeutic use | |
| Quinazolines -- administration & dosage -- adverse effects -- therapeutic use | |
| Receptor, erbB-2 -- deficiency -- metabolism | |
| Survival Analysis | |
| Treatment Outcome | |
| Tumor Markers, Biological -- metabolism | |
| Note générale: | Clinical Trial, Phase II |
| Journal Article | |
| Multicenter Study | |
| Research Support, Non-U.S. Gov't | |
| SCOPUS: ar.j | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0167-6806 |
| info:doi/10.1007/s10549-012-2126-1 | |
| info:scp/84868191989 | |
| info:pmid/22763464 | |
| PMC3409367 |
